Tricida to Report Fourth Quarter and Year-End 2020 Financial Results and Host Conference Call and Webcast on Thursday, February 25, 2021

Rhea-AI Summary

Tricida, Inc. (TCDA) will report its fourth quarter and year-end 2020 financial results on February 25, 2021, after market close. A conference call will be held at 4:30 PM ET to discuss the results and business progress. The drug candidate veverimer, aimed at treating metabolic acidosis in chronic kidney disease (CKD) patients, highlights the company’s focus on addressing a significant health issue affecting around three million people in the U.S.

Positive

• Scheduled financial results announcement may indicate ongoing transparency with investors.
• Focus on veverimer may position Tricida advantageously in the CKD treatment market.

Negative

• No current revenue streams reported, indicating potential financial uncertainty.
• Delayed commercialization or clinical results could hinder market positioning.

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its fourth quarter and year-end 2020 financial results after the close of market on Thursday, February 25, 2021. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its fourth quarter and year-end 2020 financial results and business progress. The call or webcast may be accessed as follows:

Tricida Fourth Quarter and Year-End 2020 Conference Call
Thursday, February 25, 2021 4:30 pm Eastern Time
	Webcast:	IR.Tricida.com
	Dial-in:	(800) 733-2954
	International:	(847) 413-3731
	Conference ID:	50111253

 

A replay of the webcast will be available on Tricida’s website approximately two hours following the completion of the call and will be available for up to 90 days following the presentation.

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States.

For more information about Tricida, please visit www.Tricida.com.

Contact:
Jackie Cossmon
Tricida, Inc.
Senior Vice President of Investor Relations and Communications
IR@Tricida.com

Source: Tricida, Inc.

FAQ

When will Tricida report its fourth quarter financial results for 2020?

Tricida will report its fourth quarter financial results on February 25, 2021.

What is the focus of Tricida's drug candidate veverimer?

Veverimer is designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).

How can I access Tricida's conference call for the financial results?

The conference call can be accessed via webcast at IR.Tricida.com or by dialing (800) 733-2954.

What health issue does Tricida's drug candidate address?

Veverimer addresses metabolic acidosis, a condition affecting approximately three million CKD patients in the U.S.

How long will the replay of Tricida's conference call be available?

The replay will be available for up to 90 days following the presentation.